We have determined the three-dimensional struttures of both a-and B-forms of the ligand-binding domain of the oestrogen receptor (ER) in complexes with a range of receptor agonists and ~ antagonists. Here, we summarize how these structures provide both an understanding of the
Steroid Receptor Co-Activaton and Chromatin Remodelling hERu underlie receptor activation, as well as providing a structural basis for the antagonist action of molecules, such as raloxifene.
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Introduction
T h e oestrogen receptor (ER) is a ligand-inducible transcription factor that can activate the transcription of a number of genes in many tissues [l].
T h e natural ligand for the receptor is the endogenous hormone 17-/?-oestradiol (E2), which not only controls a wide variety of physiological changes in the female reproductive organs but is also implicated in maintaining other tissues in the cardiovascular system, bone and brain. ) ]. An additional, ligand-independent, activation function 1 (AF1) activity has also been associated with the N-terminal region of ERa [7] .
We have determined the structures of the ligand-binding domain (LBD) of both ERa and ERB in complex with a variety of different ligands [5, 8] , as well as peptides derived from the nuclear receptor (NR) boxes of the T I F 2 co-activator (A. C. W. Pike, unpublished work). Analysis of these structures provides insight into the structural basis of a range of properties of the receptors. 
Structural determinants of the distinctive ERa pharmacophore
Activation by the receptor
Co-activators bind to the AF2 site through the specific binding of a helical LXXLL motif, known as an NR box [ l [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Recent structures of nuclear receptor LBDs together with appropriate peptides have shown that this helix is located in a hydrophobic cleft formed by helices 3 , 4 and 5, with the helix stabilized by capping interactions with Glu-542 and Lys-362 ( [8, 12, 20] , and A. C. W. Pike, unpublished work). This is consistent with earlier mutagenesis studies that showed the importance of this region and requirement for the C-terminal helix 12 in the structure for receptor activation [21, 22] .
Antagonism of ER
The binding of the selective antagonist RAL introduces a large pendant side chain [see Figure 2 (lower panel)] that can be accommodated only by the displacement of helix 12 [see Figure 2 (upper panel)]. Interestingly, helix 12 binds into the hydrophobic cleft formed between helices 3 , 4 and 5 on the LBD in a similar manner to the NR-box helix. In this way it masks the key residue Lys-362 identified as essential for activation [21] and antagonizes co-activator recruitment. This is one mechanism by which the AF2 function might be antagonized. An additional mechanism can be seen in the recent structure of ER LBD bound to a full antagonist (ICI 164384). Here, the secondary binding site for helix 12 is also blocked by the ligand (A. C. W. Pike, unpublished work). Figure  3 shows in schematic form these different binding modes for helix 12 and the LXXLL helical motif.
Partial agonists: ER/?
The recently obtained crystal structure of the ERB LBD complexed with the partial agonist genistein has provided a further canonical position for helix 12 [lo] . In this complex, the helix adopts a halfway position occluding the co-activator binding site but also plugging the ligand cavity. This distinctive position for the helix might be due to isoform differences between ERa and ER/3 in the residues that can make interactions between helix 12 and the rest of the protein. It can be speculated that, in the presence of sufficient suitable coactivator, helix 12 can be switched between partial and full agonist position. The structure of ERB also provides some clues to the different specificity of the receptor isoforms. However, careful ligand design will be needed to develop &selective ligands, given the rather small changes in residues lining the ligand-binding pocket (L384M and M421 I).
There are many questions about ER activation that remain unanswered by our current structural knowledge. Selective oestrogen receptor modulators such as RAL are known to have distinct effects in different target tissues, perhaps reflecting different co-activator populations. The activation function AFl in the N-terminal domain of ERa might explain some of these differences; it can be speculated that the full antagonists such as ICI 168384 disrupt the receptor sufficiently to interfere with this (or increase receptor turnover). Clearly the next stage in uncovering the structural biology of the ER will require structures of the full-length receptor, complexed perhaps with large co-activator fragments.
